Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 1/20 | 0.60 |
| ▸ | NMT1 | P30419 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30900720 | 1.00 | NMT2 (0.60) | NMT2NMT1MAPTNPSR1KDM4E | |
| SCHEMBL621104 | 0.90 | KMT2A (0.55) | NMT2NMT1MAPTNPSR1KDM4E | |
| SCHEMBL1367417 | 0.87 | MEN1 (0.65) | NMT2NMT1MAPTNPSR1KDM4E | |
| SCHEMBL1467189 | 0.87 | MAPK1 (0.63) | NMT1MAPTNPSR1KDM4EGAA | |
| SCHEMBL538115 | 0.86 | NMT1 (0.61) | NMT2NMT1MAPTNPSR1KDM4E | |
| SCHEMBL27720570 | 0.86 | MAPT (0.54) | MAPTNPSR1KDM4EGAAL3MBTL1 | |
| SCHEMBL401916 | 0.85 | MAPK1 (0.65) | MAPTNPSR1KDM4EGAAATM | |
| SCHEMBL22395756 | 0.85 | NMT2 (0.60) | NMT2NMT1MAPTNPSR1KDM4E | |
| SCHEMBL3881231 | 0.85 | MEN1 (0.53) | NMT1MAPTNPSR1KDM4EGAA | |
| SCHEMBL439008 | 0.85 | NMT2 (0.60) | NMT2NMT1MAPTNPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4155300-B1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | US HEALTH (US) | 2026-02-11 | — | — | EP | disclosed |
| CN-120129538-A | Compounds and uses thereof | 伦敦国王学院 | 2025-06-10 | — | — | CN | disclosed |
| EP-4511114-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024100095-A1 | COMPOUNDS AND THEIR USE | KING’S COLLEGE LONDON (GB) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024100095-A1 | COMPOUNDS AND THEIR USE | KING’S COLLEGE LONDON (GB) | 2024-05-16 | — | — | WO | disclosed |
| EP-3704102-B1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | US HEALTH (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3704102-B1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | US HEALTH (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| WO-2007051982-A1 | TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS | BIOLIPOX AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| EP-1603883-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-14 | — | — | EP | disclosed |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | disclosed |
| WO-2004069792-A2 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (US) | 2004-08-19 | — | — | WO | disclosed |
| WO-1999006401-A1 | 2-ARYL-2,5-DIHYDRO-PYRAZOLO[4,3-c]QUINOLIN-3-ONES AS GABA ALPHA 5 RECEPTOR INVERSE AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1999-02-11 | — | — | WO | disclosed |
| EP-0182165-B1 | THIENYL CONDENSED-PYRAZOLE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1989-08-16 | — | — | EP | disclosed |
| US-4690930-A | TRANQUILIZERS, ANTICONVULSANTS | SHIONOGI & CO., LTD (JP) | 1987-09-01 | — | — | US | disclosed |
| EP-0182165-A1 | Thienyl condensed-pyrazole derivatives | SHIONOGI & CO., LTD. (JP) | 1986-05-28 | — | — | EP | disclosed |
| US-4524146-A | NERVOUS SYSTEM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1985-06-18 | — | — | US | disclosed |
| US-4312870-A | TRANQUILIZERS, ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1982-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | NMT2 949/4885NMT1 1758/4885MAPT 2089/4885 |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | TRPV1, OPRL1, TRPV2 | NMT2 1902/4885NMT1 1394/4885MAPT 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.